drugset / Trial / NCT01280240
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
RandomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 250 mg and 500 mg in patients suffering from Chemotherapy Induced anemia.
Timeline
- Start
- 2012-03
- Primary completion
- 2012-09
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Iron isomaltoside 1000 | Unknown | 250 mg | Intravenous |
| Comparator | Iron isomaltoside 1000 | Unknown | 500 mg | Intravenous |